Navigation Links
Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
Date:4/8/2008

he improvements were achieved without any limiting next day cognitive effects. In both the Phase 1 program and the Phase 2a trial, APD125 was well tolerated at all doses investigated.

About APD125

Discovered by Arena, APD125 is a novel and oral selective inverse agonist of the 5-HT2A serotonin receptor. The vast majority of approved drugs for insomnia activate the GABA-A receptor complex in the brain, causing a general suppressive effect on the central nervous system, or CNS. These GABAergic drugs are generally associated with CNS side effects, including a sensation of dullness and lethargy upon awakening, often referred to as the "hangover effect." Other potential problems associated with the GABAergic drugs include the risk of developing tolerance and drug dependency in at-risk populations. In addition, GABAergic drugs are scheduled controlled substances by the Drug Enforcement Administration due to their potential for abuse.

By selectively targeting the 5-HT2A receptor, APD125 acts through a different mechanism than currently marketed insomnia drugs and blocks one of several CNS activating pathways. Because of the different mechanism of action, APD125 may not have the side effects or abuse potential generally associated with currently approved GABAergic drugs. Through its novel mechanism, APD125 has the potential to reduce insomnia symptoms by improving sleep maintenance.

About Insomnia

Insomnia is characterized by inadequate or poor sleep due to nonrefreshing sleep, frequent wakening with difficulty falling back to sleep, difficulty falling asleep or waking too early. Most insomnia complaints relate to sleep maintenance issues, such as waking frequently or awakening too early, as opposed to problems with sleep latency (i.e. falling asleep). About 30% of US adults report some level of insomnia in the course of a year, and about 10% of US adults indicate that their condition is chronic. In these cases, the lack of restful sleep i
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Research explores data on ... also   to   be presented ... the global specialty biopharmaceutical company, announces that it will ... American Psychiatric Association (APA) 166th Annual Meeting in ... being presented represent Shire,s ongoing commitment to the clinical ...
(Date:5/17/2013)... Rico , May 17, 2013  Serving a region ... Puerto Rico , Caribbean Imaging and Radiation Therapy (CIRT, ... radiation therapy capabilities with the acquisition of an Elekta Versa ... . Versa HD offers clinicians the versatility to deliver conventional ... body, while also enabling treatment of highly complex cancers that ...
(Date:5/17/2013)... Inc. (NASDAQ: ATOS ), The Breast Health Company™, ... Financial Officer & General Counsel, will present at the Second ... in New York City at the ... scheduled to begin at 3:30 p.m. EDT and will be ... to www.atossagenetics.com . For more information and ...
Breaking Medicine Technology:Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 2Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 3Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 4Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 5Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 6Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 7Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 8Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 9Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 10Puerto Rico's Caribbean Imaging and Radiation Therapy Center Orders Elekta's New Versa HD System for Treatment of Cancer Patients 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 3
... Calif., Oct. 20 Genoptix, Inc. (Nasdaq: ... that it ranked number 41 on Technology Fast 500™, ... media, telecommunications, life sciences and clean technology companies in ... year revenue growth during the five year period from ...
... Stryker Corporation (NYSE: SYK ) reported operating results ... Third Quarter Highlights Net ... reported) to $1,768 million Orthopaedic Implants sales increased 1.3% ... MedSurg Equipment sales increased 16.3% on a constant currency basis ...
Cached Medicine Technology:Genoptix Ranked 41st Fastest-Growing Company in North America on Deloitte's 2010 Technology Fast 500™ 2Genoptix Ranked 41st Fastest-Growing Company in North America on Deloitte's 2010 Technology Fast 500™ 3Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 2Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 3Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 4Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 5Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 6Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 7Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 8
(Date:5/18/2013)... of coffee is associated with a reduced risk ... disease, Mayo Clinic research shows. The findings were ... conference in Orlando, Fla. , PSC is ... results in inflammation and subsequent fibrosis that can ... and biliary cancer. , "While rare, PSC has ...
(Date:5/18/2013)... 18, 2013 Assisted living and ... to safety and comfort of their residents. Systems ... clients with an effective and cost-efficient solution – ... an integrated, turnkey communications solution that helps nurses ... residents independence and privacy. , The VisionLink ...
(Date:5/18/2013)... Today, Zane Benefits, Inc. published ... in Marketplaces . Zane Benefits, which provides comprehensive ... benefits, is the leader in health care reform, ... arrangements . , According to Zane Benefits’ website, ... recently released a much-anticipated statement and Q&A on ...
(Date:5/18/2013)... May 18, 2013 The Communities of ... special places we call home. These are the townships, villages ... are the locations where the people are friendly and neighbors ... viewers off the highways and shares the best in both ... nations with an American sports and film celebrity. It airs ...
(Date:5/18/2013)... “World Healthcare IT Market: Trends & Forecast (2010 – ... and opportunities in North America, Europe, Asia, & Rest ... 89 market data tables , 20 ... , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html , Early buyers will ... IT market is expected to grow from $99.6 billion ...
Breaking Medicine News(10 mins):Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 2Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:Communities of Distinction TV Presents "A Place to Call Home" Segment 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3
... More than half taking naftidrofuryl, a blood vessel ... 14 (HealthDay News) -- The prescription drug naftidrofuryl ... and enables patients to walk farther, according to ... 1,266 people with the painful condition called intermittent ...
... might add to traditional risk factors , , WEDNESDAY, May 14 ... predicted the risk of death from cardiovascular disease in a ... just a preliminary finding in a long process that might ... in addition to well-established risk factors such as high blood ...
... May 14 Learning about life, health,disability and ... LIFE Foundation unveiled a significantly enhanced version of ... Web address at, http://www.lifehappens.org . The LIFE site ... with objective, easy-to-understand educational,content on all the major ...
... Proposals Reflect Ideas Championed by NCPA,s Family Policy ... embarked,in a new direction aimed at helping working ... Representatives announced a slate of legislation aimed,at simplifying ... laws. The,legislation, titled the American Families Agenda, contains ...
... are estimated to be affected by the devastation caused ... by researchers from the Johns Hopkins Bloomberg School of ... Systems (GIS), the researchers calculated the likely distribution of ... developed maps of the regions at greatest risk from ...
... Offers Precision Laser Technology for Custom Contouring of Women,s ... ... Syneron,s LipoLite, an FDA approved,minimally invasive procedure used to liquefy and remove ... United States at Ariana,Cosmetic Surgery & Laser Center in Las Vegas. LipoLite ...
Cached Medicine News:Health News:Common Drug Eases Leg Pain From Walking 2Health News:Biomarkers Predict Heart Deaths 2Health News:Biomarkers Predict Heart Deaths 3Health News:LIFE Foundation Launches Lifehappens.org to Help Consumers Make Smart Insurance-Buying Decisions 2Health News:LIFE Foundation Launches Lifehappens.org to Help Consumers Make Smart Insurance-Buying Decisions 3Health News:New Initiatives Provide Flexibility, Fairness for Families 2Health News:Estimated 3.2 million Burmese potentially affected by cyclone 2Health News:Las Vegas Plastic Surgeons First in U.S. to Offer LipoLite 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: